Clearmind reports safe treatment progression in third cohort of Phase I/IIa AUD trial
Clearmind has successfully treated its third cohort in the FDA-approved Phase I/IIa trial of CMND-100 at Yale and Johns Hopkins with no serious adverse events reported. The multinational study continues to assess safety, tolerability, pharmacokinetics and preliminary efficacy of the non-hallucinogenic neuroplastogen in moderate to severe alcohol use disorder.
1. Third Cohort Advancement
Clearmind has initiated and successfully continued dosing of its third cohort in the FDA-approved Phase I/IIa study of CMND-100 at Yale University and Johns Hopkins University. This expansion follows recent enrollment progress and underscores the trial’s momentum across leading U.S. medical centers.
2. Safety and Tolerability
To date, no serious adverse events have been reported among participants in the third cohort, reinforcing prior safety and tolerability observations from earlier cohorts. Ongoing monitoring includes standardized assessments of vital signs, laboratory parameters and patient‐reported outcomes.
3. Study Design and Objectives
The multinational, multicenter trial is designed to evaluate CMND-100’s safety, tolerability, pharmacokinetics and preliminary efficacy in patients with moderate to severe alcohol use disorder. Key endpoints include changes in craving scores, drinking days and biomarker profiles over the dosing period.
4. Future Plans
Clearmind plans to complete the Phase I/IIa trial later this year before advancing CMND-100 into pivotal studies. Successful topline results could position the therapy for accelerated development and potential regulatory designations aimed at treating alcohol use disorder.